Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Annals of the Rheumatic Diseases
D A IsenbergDaniel J Wallace

Abstract

Evaluate efficacy and safety of tabalumab, a human IgG4 monoclonal antibody that binds and neutralises membrane and soluble B-cell activating factor (BAFF) versus placebo plus standard of care (SoC) in patients with systemic lupus erythematosus (SLE). This phase III, 52-week study randomised 1164 patients with moderate-to-severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index ≥6 at baseline). Patients received SoC plus subcutaneous injections of tabalumab or placebo, starting with a loading dose (240 mg) at week 0 and followed by 120 mg every two weeks (120 Q2W, n=387), 120 mg every four weeks (120 Q4W, n=389) or placebo Q2W (n=388). proportion of patients achieving SLE Responder Index 5 (SRI-5) response at week 52. Similar proportions of patients in each group achieved SRI-5 response at week 52 (120 Q2W: 31.8%; 120 Q4W: 35.2% and placebo: 29.3%). Key secondary endpoints were not met. In a sensitivity analysis not excluding patients who decreased antimalarials or immunosuppressants, SRI-5 response was achieved with 120 Q4W (37.0% vs 29.8% placebo; p=0.021), but not 120 Q2W (34.1%; p=0.171). Significant reductions in anti-dsDNA antibodies, increases in C3 and C4, and reductions in t...Continue Reading

References

Jun 8, 1999·The Journal of Experimental Medicine·P SchneiderJ Tschopp
Dec 16, 2005·The New England Journal of Medicine·Michelle PetriUNKNOWN OC-SELENA Trial
Feb 20, 2007·Lancet·David P D'CruzGraham R V Hughes
Nov 21, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jaime R DarceDiane F Jelinek
Nov 30, 2007·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Yoshiya Tanaka
May 5, 2009·The Journal of Clinical Investigation·Michael P CancroMunther A Khamashta
Aug 29, 2009·Arthritis and Rheumatism·Richard A FurieWilliam W Freimuth
Oct 2, 2013·Annals of Internal Medicine·Marianthi KiriakidouSankey Williams
Feb 14, 2014·Expert Opinion on Therapeutic Targets·William Stohl
Apr 8, 2014·Academic Radiology·Koichiro FutatsuyaYukunori Korogi
Jun 3, 2014·Lancet·Larissa LisnevskaiaDavid Isenberg
Jul 19, 2014·Rheumatic Diseases Clinics of North America·Ellen M Ginzler, Mary Anne Dooley

❮ Previous
Next ❯

Citations

May 10, 2016·Expert Opinion on Drug Safety·Alba Velo-GarcíaDavid Isenberg
Apr 1, 2016·Expert Opinion on Biological Therapy·Mo Yin Mok, Yehuda Shoenfeld
Jun 15, 2016·Current Rheumatology Reports·Helena Hiemisch Lobo BorbaRoberto Pontarolo
Jun 17, 2016·Journal of Internal Medicine·A A Bengtsson, L Rönnblom
Oct 26, 2016·Journal of Autoimmunity·L Durcan, M Petri
Oct 26, 2016·Journal of Autoimmunity·Mariele GattoAndrea Doria
Jul 20, 2016·Clinical Immunology : the Official Journal of the Clinical Immunology Society·William Stohl, Agnes Banfalvi
Sep 3, 2016·Archivum Immunologiae Et Therapiae Experimentalis·Juan Pablo Mackern-ObertiAlexis M Kalergis
Sep 23, 2016·Digestive Diseases and Sciences·Mathieu UzzanSaurabh Mehandru
Nov 15, 2016·Expert Review of Clinical Immunology·Pedro MotaDavid Isenberg
Jun 23, 2016·Annals of the Rheumatic Diseases·Ronald van Vollenhoven
Sep 25, 2016·Joint, Bone, Spine : Revue Du Rhumatisme·Estibaliz LazaroChristophe Richez
Jan 25, 2017·Current Opinion in Rheumatology·Michael A PaleyAlfred H J Kim
Aug 9, 2016·Lupus·M A MahieuR Ramsey-Goldman
Jul 1, 2017·Current Opinion in Rheumatology·Khaled MahmoudEdward M Vital
Nov 5, 2017·Current Rheumatology Reports·Stamatis-Nick C Liossis, Chrysanthi Staveri
Jul 25, 2018·Expert Opinion on Biological Therapy·Zdenka Hruskova, Vladimir Tesar
Dec 13, 2018·Current Opinion in Rheumatology·Eva SchrezenmeierThomas Dörner
Mar 16, 2017·Nutrition Research Reviews·Marina Aparicio-SotoCatalina Alarcón-de-la-Lastra
Oct 21, 2016·Nature Reviews. Rheumatology·Thomas Dörner, Peter E Lipsky
Feb 19, 2016·Nature Reviews. Rheumatology·Michael R Ehrenstein, Charlotte Wing
Jan 14, 2019·Annals of the Rheumatic Diseases·Maria Dall'EraPeter E Lipsky
Jun 6, 2019·Nature Reviews. Rheumatology·Grainne Murphy, David A Isenberg
Oct 29, 2019·Expert Opinion on Drug Safety·Leanna M Wise, William Stohl
Dec 14, 2019·Nature Reviews. Rheumatology·Kathryn M KingsmorePeter E Lipsky
Sep 8, 2019·Arthritis & Rheumatology·William StohlChaim O Jacob
Oct 17, 2019·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·D BakerG Giovannoni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Related Papers

© 2021 Meta ULC. All rights reserved